AU2018366270B2 - Caffeic acid derivatives for treating hyperproliferative diseases - Google Patents

Caffeic acid derivatives for treating hyperproliferative diseases Download PDF

Info

Publication number
AU2018366270B2
AU2018366270B2 AU2018366270A AU2018366270A AU2018366270B2 AU 2018366270 B2 AU2018366270 B2 AU 2018366270B2 AU 2018366270 A AU2018366270 A AU 2018366270A AU 2018366270 A AU2018366270 A AU 2018366270A AU 2018366270 B2 AU2018366270 B2 AU 2018366270B2
Authority
AU
Australia
Prior art keywords
compound
groups
cooh
nhch
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018366270A
Other languages
English (en)
Other versions
AU2018366270A1 (en
Inventor
Izabela Fokt
Arumugan JAYAKUMAR
Waldemar Priebe
Stanislaw Skora
Radjendirane VENUGOPAL
Rafal Zielinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2018366270A1 publication Critical patent/AU2018366270A1/en
Application granted granted Critical
Publication of AU2018366270B2 publication Critical patent/AU2018366270B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2018366270A 2017-11-10 2018-11-09 Caffeic acid derivatives for treating hyperproliferative diseases Ceased AU2018366270B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584591P 2017-11-10 2017-11-10
US62/584,591 2017-11-10
PCT/US2018/059975 WO2019094689A1 (en) 2017-11-10 2018-11-09 Caffeic acid derivatives for treating hyperproliferative diseases

Publications (2)

Publication Number Publication Date
AU2018366270A1 AU2018366270A1 (en) 2020-05-21
AU2018366270B2 true AU2018366270B2 (en) 2023-04-20

Family

ID=64664389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018366270A Ceased AU2018366270B2 (en) 2017-11-10 2018-11-09 Caffeic acid derivatives for treating hyperproliferative diseases

Country Status (14)

Country Link
US (1) US10703721B2 (https=)
EP (1) EP3707125A1 (https=)
JP (1) JP7428642B2 (https=)
KR (1) KR20200085815A (https=)
CN (1) CN111417625A (https=)
AU (1) AU2018366270B2 (https=)
BR (1) BR112020009219A2 (https=)
CA (1) CA3081975A1 (https=)
EA (1) EA202091164A1 (https=)
MX (1) MX2020004871A (https=)
SG (1) SG11202004230XA (https=)
TW (1) TWI846678B (https=)
UA (1) UA126821C2 (https=)
WO (1) WO2019094689A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12539503B2 (en) 2022-08-03 2026-02-03 The University Of Toledo Environmentally friendly polymeric sorbent material for the extraction and determination of rare earth elements, thorium, and uranium

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040527A2 (en) * 2010-09-24 2012-03-29 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
WO2015054555A1 (en) * 2013-10-10 2015-04-16 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
WO2015187427A1 (en) * 2014-06-02 2015-12-10 Pharmakea, Inc. Deubiquitinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
WO2003068157A2 (en) 2002-02-11 2003-08-21 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
PT1701941E (pt) 2003-12-11 2012-08-03 Univ Texas Compostos para o tratamento de doenças proliferativas celulares
BRPI0709916B8 (pt) 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
WO2008005954A2 (en) 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
NZ590372A (en) * 2008-07-08 2012-09-28 Univ Texas Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
US20130129675A1 (en) 2009-12-04 2013-05-23 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
WO2015183987A1 (en) 2014-05-27 2015-12-03 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040527A2 (en) * 2010-09-24 2012-03-29 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
WO2015054555A1 (en) * 2013-10-10 2015-04-16 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
WO2015187427A1 (en) * 2014-06-02 2015-12-10 Pharmakea, Inc. Deubiquitinase inhibitors

Also Published As

Publication number Publication date
WO2019094689A1 (en) 2019-05-16
MX2020004871A (es) 2020-08-06
EP3707125A1 (en) 2020-09-16
JP2021502374A (ja) 2021-01-28
TWI846678B (zh) 2024-07-01
UA126821C2 (uk) 2023-02-08
CN111417625A (zh) 2020-07-14
AU2018366270A1 (en) 2020-05-21
KR20200085815A (ko) 2020-07-15
CA3081975A1 (en) 2019-05-16
TW201922707A (zh) 2019-06-16
US20190177276A1 (en) 2019-06-13
JP7428642B2 (ja) 2024-02-06
SG11202004230XA (en) 2020-06-29
BR112020009219A2 (pt) 2020-10-20
EA202091164A1 (ru) 2020-08-03
US10703721B2 (en) 2020-07-07

Similar Documents

Publication Publication Date Title
AU2021200969B2 (en) Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
RU2194699C2 (ru) 1-фенил-бензимидазольные соединения, фармацевтическая композиция и способ лечения расстройства или заболевания, чувствительного к модуляции гамка-рецепторного комплекса центральной нервной системы
EP1877390B1 (en) Benzisoxazole piperazine compounds and methods of use thereof
EP2656841A1 (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2014346483B2 (en) Biphenylamide derivative Hsp90 inhibitors
AU2018366270B2 (en) Caffeic acid derivatives for treating hyperproliferative diseases
WO2017223514A1 (en) Lxr inverse agonists for treatment of cancer
JP2008528677A (ja) Ｃｎｓの疾患および障害の処置のための四環系モノアミン再取り込み阻害薬
CN121378212A (zh) 2-(哌啶烷基)哒嗪酮类化合物及其制备方法和用途
BR112016029672B1 (pt) Composto bifenil amida com grupos éter modificados como inibidores de hsp90 e indutores de hsp70, composição farmacêutica que compreende o dito composto, bem como uso terapêutico do mesmo
BRPI0610258A2 (pt) composto ou um sal farmaceuticamente eficaz do mesmo, composição farmacêutica, e, uso de um composto
JP2020189788A (ja) 睡眠誘導剤である複素環化合物
HK40001441A (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
HK40001441B (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
HK1122796B (en) Benzisoxazole piperazine compounds and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired